Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care.